[go: up one dir, main page]

AR066716A1 - Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones - Google Patents

Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones

Info

Publication number
AR066716A1
AR066716A1 ARP080102198A ARP080102198A AR066716A1 AR 066716 A1 AR066716 A1 AR 066716A1 AR P080102198 A ARP080102198 A AR P080102198A AR P080102198 A ARP080102198 A AR P080102198A AR 066716 A1 AR066716 A1 AR 066716A1
Authority
AR
Argentina
Prior art keywords
compositions
pal
methods
variant
processories
Prior art date
Application number
ARP080102198A
Other languages
English (en)
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR066716A1 publication Critical patent/AR066716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Fenilalanina amoníaco liasa (PAL) producida por procariontes, en donde dicha PAL procariotica donde la variante PAL tiene mayor actividad de conversion de la fenilalanina y/o una menor inmunogenicidad en comparacion con un PAL de tipo silvestre. Además composiciones de PAL bacteriana y sus fragmentos, mutantes, variantes y análogos biologicamente activos, así como métodos para la produccion, purificacion y uso de tales composiciones para fines terapéuticos e industriales. Reivindicacion 4: La variante de PAL de la reivindicacion 3, caracterizada porque la variante es PAL de Anabaena variabilis.
ARP080102198A 2007-05-25 2008-05-23 Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones AR066716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

Publications (1)

Publication Number Publication Date
AR066716A1 true AR066716A1 (es) 2009-09-09

Family

ID=39868905

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102198A AR066716A1 (es) 2007-05-25 2008-05-23 Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones
ARP180100106A AR110834A2 (es) 2007-05-25 2018-01-17 MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180100106A AR110834A2 (es) 2007-05-25 2018-01-17 MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal)

Country Status (29)

Country Link
US (1) US7534595B2 (es)
EP (2) EP2152868B1 (es)
JP (1) JP5670183B2 (es)
KR (2) KR20150038753A (es)
CN (1) CN101842482B (es)
AR (2) AR066716A1 (es)
AU (1) AU2008263190B2 (es)
BR (1) BRPI0811267B8 (es)
CA (1) CA2687450C (es)
CL (1) CL2008001497A1 (es)
CY (2) CY1116894T1 (es)
DK (1) DK2152868T3 (es)
EA (1) EA018443B1 (es)
ES (1) ES2551315T3 (es)
HR (1) HRP20151268T1 (es)
HU (2) HUE025784T2 (es)
IL (1) IL202132A (es)
LT (1) LTC2152868I2 (es)
LU (1) LUC00133I2 (es)
MX (1) MX2009012453A (es)
MY (1) MY151413A (es)
NL (1) NL301011I2 (es)
NO (1) NO2019037I1 (es)
PE (1) PE20090315A1 (es)
PL (1) PL2152868T3 (es)
PT (1) PT2152868E (es)
SI (1) SI2152868T1 (es)
TW (1) TWI418633B (es)
WO (1) WO2008153776A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011097335A2 (en) * 2010-02-04 2011-08-11 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
EP3222288A1 (en) * 2012-07-27 2017-09-27 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
HRP20190928T1 (hr) 2013-04-18 2019-07-26 Codexis, Inc. Modificirani fenilalanin amonijak-liazni polipeptidi
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
PL3125927T3 (pl) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Sposoby i kompozycje do immunomodulacji
EP3928787A1 (en) * 2014-04-16 2021-12-29 Codexis, Inc. Engineered tyrosine ammonia lyase
HUE062016T2 (hu) 2014-12-22 2023-09-28 Codexis Inc Humán alfa-galaktozidáz variánsok
TWI797060B (zh) * 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
WO2018043546A1 (ja) * 2016-08-30 2018-03-08 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
BR112019016634A2 (pt) * 2017-02-13 2020-04-07 Codexis Inc polipeptídeos, sequência de polinucleotídeos modificados por engenharia, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo de fenilalanina amônia liase modificado por engenharia em uma célula hospedeira e para tratar e/ou prevenir os sintomas de fenilcetonúria em um indivíduo, composição, e, uso
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
AU2019265560A1 (en) 2018-05-09 2020-11-26 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CA3102968A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
US11198861B2 (en) * 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
KR102898199B1 (ko) 2018-12-20 2025-12-09 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
CA3152763A1 (en) 2019-08-30 2021-03-04 Codexis, Inc. Engineered lipase variants
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド 操作された酸性アルファ－グルコシダーゼバリアント
IL295169A (en) 2020-02-04 2022-09-01 Codexis Inc Engineered leucine decarboxylases
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
CN117098847A (zh) 2020-08-28 2023-11-21 科德克希思公司 工程化蛋白酶变体
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
US11918633B2 (en) * 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
TW202313969A (zh) 2021-05-21 2023-04-01 美商克迪科思股份有限公司 經工程化的甲硫胺酸γ解離酶變異體
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
US12502421B2 (en) 2021-11-01 2025-12-23 Syntis Bio, Inc. Engineered leucine decarboxylases
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025106759A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP2930723B2 (ja) * 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
DE69233695T2 (de) * 1992-12-04 2008-01-24 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (es) * 1993-06-25 1993-06-25 Novo Nordisk As
EP1188448A3 (en) * 1994-03-15 2002-04-17 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) * 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
JP2003516360A (ja) * 1999-12-09 2003-05-13 カイロン コーポレイション 中枢神経系およびリンパ系に対するサイトカイン投与方法
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2406390A1 (en) * 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP1309705B1 (en) * 2000-07-25 2012-02-15 Immunomedics Inc. Multivalent target binding protein
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
CN102061288A (zh) * 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
AU2003290780B2 (en) 2002-11-14 2009-05-07 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (FAAH)
WO2004111089A2 (en) * 2003-06-11 2004-12-23 WYETH A Corporaton of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1814984A2 (en) 2004-09-17 2007-08-08 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US20090038023A1 (en) * 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
PT2152868E (pt) 2015-11-13
PL2152868T3 (pl) 2016-01-29
MX2009012453A (es) 2010-01-25
EA018443B1 (ru) 2013-08-30
LTPA2019517I1 (lt) 2019-10-25
KR20150038753A (ko) 2015-04-08
ES2551315T3 (es) 2015-11-18
IL202132A0 (en) 2010-06-16
EP2152868A1 (en) 2010-02-17
WO2008153776A1 (en) 2008-12-18
EP2657335A1 (en) 2013-10-30
EP2152868B1 (en) 2015-09-02
CY2019039I1 (el) 2020-05-29
HRP20151268T1 (hr) 2015-12-18
CN101842482A (zh) 2010-09-22
NL301011I1 (nl) 2019-10-16
KR101603796B1 (ko) 2016-03-17
BRPI0811267A2 (pt) 2014-10-07
BRPI0811267B8 (pt) 2021-05-25
HUS1900049I1 (hu) 2019-11-28
LTC2152868I2 (lt) 2020-09-25
AR110834A2 (es) 2019-05-08
LUC00133I1 (es) 2019-10-16
HUE025784T2 (en) 2016-05-30
KR20100024437A (ko) 2010-03-05
CA2687450C (en) 2019-03-26
WO2008153776A8 (en) 2009-07-30
PE20090315A1 (es) 2009-03-19
MY151413A (en) 2014-05-30
LUC00133I2 (es) 2020-07-16
CY2019039I2 (el) 2020-05-29
NL301011I2 (nl) 2020-05-13
SI2152868T1 (sl) 2015-12-31
JP5670183B2 (ja) 2015-02-18
AU2008263190A1 (en) 2008-12-18
AU2008263190B2 (en) 2014-04-17
JP2010529835A (ja) 2010-09-02
US20080008695A1 (en) 2008-01-10
CA2687450A1 (en) 2008-12-18
BRPI0811267B1 (pt) 2020-11-10
NO2019037I1 (no) 2019-10-16
HK1135141A1 (zh) 2010-05-28
DK2152868T3 (en) 2015-11-16
EA200970980A1 (ru) 2010-04-30
US7534595B2 (en) 2009-05-19
CL2008001497A1 (es) 2009-01-09
TWI418633B (zh) 2013-12-11
CY1116894T1 (el) 2017-04-05
TW200902052A (en) 2009-01-16
CN101842482B (zh) 2014-10-22
IL202132A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
AR066716A1 (es) Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones
AR067972A1 (es) Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer
WO2011097335A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
IN2012DN00801A (es)
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2007001283A1 (es) Compuestos derivados de pirazinona
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
EA200901432A1 (ru) Новые аспарагиназы и их применение
EA200900568A1 (ru) Модифицированные цианобактерии
ATE485304T1 (de) Muteine von tearlipocalin und verfahren zu deren gewinnung
NZ703093A (en) Purification of iduronate-2-sulfatase
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
WO2008102720A1 (ja) 光学活性３－アミノピペリジン又はその塩の製造方法
UA95083C2 (ru) Азеотропная или близкая к азеотропной композиции, которые содержат 1,1,1,2,3-пентафторопропен и фтороводород, способы отделения и получения 1,1,1,2,3-пентафторопропена
EA201171141A1 (ru) Твердый ретигабин в некристаллической форме
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
AR087168A1 (es) Compuesto derivado de pirimidina sulfonamida
CL2008001648A1 (es) Compuestos derivados de triazol[1,5-a]quinolina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como asma, epoc, artritis reumatoide, isquemia, entre otras.

Legal Events

Date Code Title Description
FG Grant, registration